LB Pharmaceuticals announces positive schizophrenia trial data
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
List view / Grid view
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
Researchers at Washington University are developing a vaccine using nanofiber technology to prevent dementia, offering a safer and more effective alternative to current treatments.
Huntsman Cancer Institute researchers have identified a gene variant in Andean populations that could predict blood cancer treatment outcomes and potentially lead to targeted therapies.
A new peptide-based eye drop treatment for dry AMD offers a non-invasive, effective alternative to injectable therapies, enhancing patient convenience and care.
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
Researchers at the University of Pennsylvania have engineered lipid nanoparticles to target neurons, advancing mRNA treatments for brain diseases.
A breakthrough in molecular imaging could transform how doctors target solid tumours, offering more personalised and effective treatment options.
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
Hydrocelin shows promising preclinical results in treating osteoarthritis, offering pain relief and potential joint protection with no observed side effects.
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.